Skip to main content

Commentary: Pharmacy benefit managers, not Big Pharma, responsible for high drug prices

Flovent was pulled from shelves, but don't blame its maker: GSK chose to switch to a lower-priced generic. The pharmacy benefit managers made more money covering the more expensive version — and that's why they pulled it from the shelves, writes two experts.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.